文献速递泌尿男性生殖肿瘤

CAN-2409联合放疗治疗局限性前列腺癌的III期随机双盲安慰剂对照试验

Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Oncol · 2026-01-01

这项III期随机双盲安慰剂对照试验纳入745例中高危局限性前列腺癌患者,比较前列腺内注射aglatimagene besadenovec(CAN-2409)联合伐昔洛韦与安慰剂联合伐昔洛韦加标准放疗的疗效。两组≥3级治疗相关不良事件发生率相似,未报告治疗相关死亡。

要点

  • 两组≥3级不良事件发生率相近(8% vs 7%),未增加临床显著毒性。
  • 最常见≥3级不良事件为急性肾损伤,两组均为2%。

核心结论

  • 在标准放疗基础上加用CAN-2409联合伐昔洛韦,较安慰剂联合伐昔洛韦显著延长局限性前列腺癌患者的无病生存期,且未增加临床显著毒性。

研究设计与样本

  • III期、多中心、随机、双盲、安慰剂对照试验,在美国和波多黎各51个中心(26个社区中心和25个机构或军队中心)开展。
  • 纳入745例中高危局限性前列腺癌患者,按2:1随机分配至CAN-2409联合伐昔洛韦组(n=496)或安慰剂联合伐昔洛韦组(n=249),随机分层因素为风险类别和雄激素剥夺治疗(ADT)使用情况。
  • 主要终点为意向治疗人群的无病生存期,定义为从随机化到前列腺癌复发或死亡的时间;安全性评估纳入至少接受一次注射的所有个体。

主要发现

  • ≥3级治疗中出现的不良事件(TEAE)在CAN-2409组479例中发生40例(8%),安慰剂组232例中发生17例(7%)。
  • 两组最常见的≥3级TEAE均为急性肾损伤(CAN-2409组9例[2%],安慰剂组4例[2%])。
  • 严重不良事件在CAN-2409组479例中发生28例(6%),安慰剂组232例中发生17例(7%)。
  • 治疗相关严重不良事件在CAN-2409组8例(2%)中发生(4例急性肾损伤、2例发热、各1例流感样症状和尿潴留),安慰剂组5例(2%)中发生(4例急性肾损伤、各1例肌酐升高和皮疹;1例患者报告2起严重不良事件);未报告治疗相关死亡。

临床怎么用

  • 对于计划接受根治性放疗的中高危局限性前列腺癌患者,可考虑在标准放疗基础上加用前列腺内注射CAN-2409联合伐昔洛韦,以改善无病生存期。
  • 治疗期间需监测急性肾损伤等不良事件,但整体≥3级毒性发生率与安慰剂组相似,未显著增加临床显著毒性。

局限性

  • 长期随访正在进行中,无病生存期数据尚未成熟。
  • 研究人群以白人为主(591例[79%]),黑人121例(16%),其他种族代表性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: About 30% of men with localised prostate cancer undergoing radiotherapy with curative intent have disease recurrence associated with progression-related symptoms and substantial toxicity of salvage therapies. Previous studies with aglatimagene besadenovec (CAN-2409, hereafter referred to as aglatimagene) showed synergy with radiation and immune-mediated cytotoxicity in patients with prostate cancer. We aimed to assess whether addition of aglatimagene plus prodrug (valacyclovir) to standard-of-care external beam radiation therapy (EBRT) could improve disease-free survival in this population. METHODS: We conducted a phase 3, randomised, double-blind, placebo-controlled trial at 51 medical centres (26 community and 25 institutional or military) across the USA and Puerto Rico in patients with intermediate or high-risk prostate cancer. Patients aged at least 18 years who were planning to undergo EBRT and with an Eastern Cooperative Oncology Group score of 0-2 were eligible. Patients were randomly assigned (2:1) via central block-randomisation to receive either three courses of intraprostatic aglatimagene (5 × 1011 viral particles) plus valacyclovir or placebo plus valacyclovir, with randomisation stratified by risk category and androgen deprivation therapy (ADT) use. Patients received standard-of-care EBRT (78 Gy in 2 Gy fractions) or hypofractionated EBRT (60 Gy in 3 Gy fractions or 70 Gy in 2·5 Gy fractions) with optional ADT. The primary endpoint was disease-free survival, defined as time-from-randomisation to prostate cancer recurrence or death in the intent-to-treat population (all randomly assigned patients). Safety was assessed in all individuals who received at least one injection. The trial is registered at ClinicalTrials.gov, NCT01436968, and long-term follow-up is ongoing. FINDINGS: Between Feb 21, 2012, and Sept 9, 2021, 745 men (591 [79%] White, 121 [16%] Black) were randomly assigned to receive aglatimagene plus valacyclovir (n=496) or placebo plus valacyclovir (n=249). After a median follow-up of 50·3 months (IQR 35·2-63·3), median disease-free survival was not reached (95% CI 121·78 to not reached) in the aglatimagene plus valacyclovir group versus 86·1 (IQR 29·7-143·0) months in the placebo plus valacyclovir group (hazard ratio 0·70, 95% CI 0·52-0·94; p=0·016). Treatment-emergent adverse events (TEAEs) of grade 3 or worse occurred in 40 (8%) of 479 patients in the aglatimagene group and 17 (7%)of 232 patients in the placebo group. The most common TEAE of grade 3 or worse was acute kidney injury in both the aglatimagene group (nine [2%] of 479 patients) and the placebo group (four [2%] of 232 patients). Serious adverse events occurred in 28 (6%) of 479 patients in the aglatimagene group and 17 (7%) of 232 in the placebo group. Treatment-related serious adverse events occurred in eight (2%) patients in the aglatimagene group (four acute kidney injury, two pyrexia, and one each influenza-like symptoms and urinary retention) and five (2%) in the placebo group (four acute kidney injury, and one each increased creatinine levels and skin rash; one patient reported two serious adverse events). No treatment-related deaths were reported. INTERPRETATION: Aglatimagene plus valacyclovir was associated with longer disease-free survival than placebo plus valacyclovir when added to standard of radiotherapy for the treatment of localised prostate cancer, offering a meaningful benefit without increasing clinically significant toxicity. FUNDING: Candel Therapeutics and US National Institutes of Health.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. DeWeese TL, Manzanera A, Sylvester J, et al. Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2026. PMID: 42225101. doi:10.1016/S1470-2045(26)00071-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。